Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd
Portage Biotech Divests Portage Pharmaceuticals Limited to Juvenescence Ltd Portage may be entitled to up to USD $244 million in future milestone payments -Toronto, Ontario– – Portage Biotech Inc. a clinical stage immuno-oncology company accelerating research and development to overcome immune resistance, today announced the divestment of its three legacy businesses; Portage Pharmaceuticals Limited including subsidiaries Portage Glasgow Ltd. and EyGen Ltd, to Juvenescence Ltd., a company … Portage may be entitled to up to USD $244 million in future milestone payments – Toronto, Ontari...
Source: investingnews.com